Arch-Backed SciNeuro Pharmaceuticals Raises $53M for Neurodegenerative Disease Research

SciNeuro Pharmaceuticals, a biotechnology startup founded in 2020, has secured $53 million in equity financing to advance its drug development programs targeting neurodegenerative disorders. The funding round, led by Arch Venture Partners and China-based LAV, marks a significant milestone for the company as it seeks to address challenging areas of neurological drug development.

Investment Details and Company Strategy

The $53 million raised will support SciNeuro's efforts to develop therapeutics for a range of disease pathways associated with conditions such as Alzheimer's and Parkinson's. This investment represents the latest in a series of Arch Venture Partners' contributions to the neuroscience field, following recent funding rounds for other companies like Aspen Neuroscience and Tenvie Therapeutics.

SciNeuro's approach focuses on innovative therapies targeting key proteins implicated in neurodegenerative processes. The company's research includes work on beta-amyloid, a protein associated with Alzheimer's disease, and LRRK2, which has strong links to Parkinson's disease.

Key Appointments and Additional Funding

Alongside the equity financing, SciNeuro announced the appointment of Hogan Wan as Chief Financial Officer. Wan brings over a decade of experience in biopharma corporate finance and investment banking, most recently serving as head of investor relations and strategy at Ascentage Pharma, where he led the company's initial public offering process.

In addition to the equity financing, SciNeuro has received a $5 million non-dilutive research grant from The Michael J. Fox Foundation for Parkinson's Research, further bolstering its resources for neurodegenerative disease research.

Arch Venture Partners' Continued Investment in Neuroscience

Arch Venture Partners has been increasingly active in the neuroscience sector, participating in at least 74 funding rounds since 2022, including 13 in 2025 alone. The firm's commitment to the field is underscored by its recent raise of $3 billion to invest in startups, with a significant portion directed towards companies focusing on nervous system disorders.

This trend highlights the growing interest in addressing neurodegenerative diseases, despite the historically challenging nature of drug development in this area. The investment in SciNeuro Pharmaceuticals represents a strategic bet on the potential for breakthrough treatments in a field known for its complexity and high failure rates.